This article is more than 5 years old. Information may no longer be current.

Statins, NSAIDs may slow neoplastic progression from Barrett's esophagus

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Patients with Barrett’s esophagus who used statins or nonsteroidal anti-inflammatory drugs reduced their risk for neoplastic progression, a study found.

An added protective effect was observed in patients who received a combination of NSAIDs and statins.

Researchers in the Netherlands collected prospective data on medication use for 570 patients with Barrett’s esophagus. During a median follow-up period of 4.5 years, 7% of study participants developed high-grade dysplasia and adenocarcinoma.

After study participants were diagnosed with Barrett’s esophagus, 56% used NSAIDs (median: 2 months), 28% used aspirin (median: 5 years), 37% used statins (median: 5 years), and 19% used NSAIDs and statins (median: 5 years).

Reduced risk of neoplastic progression was associated with NSAID use (HR=0.47; P=.030) and statin use (HR=0.46; P=.048). A combination of NSAIDs and statins increased the protective effect (HR=0.22; P=.028).

Disclosure: The researchers report no relevant financial disclosures.